Rosen Law Firm has reminded purchasers of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 that the lead plaintiff deadline in an already filed securities class action is October 5, 2026. The lawsuit alleges defendants gave investors overly positive statements on the expected timeline for expanded insurance coverage of the company’s epinephrine nasal spray, neffy, through CVS Caremark—including confidence coverage would begin July 1, 2026 for the summer and back-to-school allergy seasons—while disseminating false and misleading statements or concealing material adverse facts, causing shares to trade at artificially inflated prices and investors to suffer damages when the truth emerged. Separately, the Law Offices of Frank R. Cruz notified investors of securities class actions for Taboola.com Ltd., GoDaddy Inc., Aevex Corp. and Fractyl Health, Inc., each with an October 20, 2026 lead plaintiff deadline, over alleged failures to disclose rising low-quality publishers at Taboola, an ineffective high-intent strategy and promotional dotcom discounts at GoDaddy, a pre-arranged plan to lift Aevex’s 180-day lock-up so Madison could sell in a secondary offering that yielded no proceeds to Aevex, and overstated Revita efficacy plus compromised REMAIN-1 Midpoint Cohort results at Fractyl Health. Glancy Prongay Wolke & Rotter LLP also detailed an Alarum Technologies Ltd. securities fraud action covering March 20, 2025 through July 2, 2026, with the same October 5, 2026 lead plaintiff deadline, alleging subsidiary NetNut linked customer home internet devices into another network without consent. Investors who suffered losses may contact the respective firms about their rights.